Correvio licenses XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension (PAH) for select markets in Europe and the Middle East from SteadyMed Therapeutics. Recently, Correvio also licensed ZEVTERA®/MABELIO® (ceftobiprole medocaril), a semi-synthetic, pro-drug form of a cephalosporin antibiotic for the treatment of community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) excluding ventilator acquired pneumonia (VAP) in adults for select European markets and Israel from Basilea Pharmaceutica.
Correvio also has two marketed, in-hospital, cardiology products: BRINAVESS® (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Correvio commercializes BRINAVESS® and AGGRASTAT® directly in European markets, and through a network of partners in ex-US global markets . Correvio also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets.